Home / Themes / Consumer Trends '26: Healthspan & Longevity

Consumer Trends '26: Healthspan & Longevity (open on stockthemes)

Last updated

Theme thesis · 5/5 sections · Tickers 10 with notes · 6 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Proactive healthcare monetization is accelerating as preventive diagnostics, next-gen metabolic therapeutics, and consumer biowearables shift spending upstream

Thesis

Proactive healthcare monetization is accelerating as preventive diagnostics, next-gen metabolic therapeutics, and consumer biowearables shift spending upstream from sick care. Sustained multi-year upside hinges on expanding commercial and Medicare reimbursement, while cash-burn rates, pricing erosion, and rigorous clinical utility hurdles present near-term execution risks.

Bull case

  • Expanding commercial and Medicare coverage, alongside robust clinical validation for liquid biopsy multi-cancer screening, hereditary genomics, and continuous metabolic sensing, drives surging test volumes and establishes high-margin recurring diagnostics before symptomatic disease develops.

  • Breakthroughs in next-generation incretins, oral cardiometabolic therapies, and translational aging-biology drugs are establishing preventive pharmacotherapy categories that arrest chronic disease progression and preserve physical function over extended lifespans.

  • Structural reallocation of consumer discretionary and payer spending toward preventative vaccination, routine biomarker diagnostics, affordable fitness memberships, and functional nutrition creates resilient, multi-channel recurring cash flows across diversified demographic cohorts.

Bear case

  • Multi-cancer early detection and novel screening modalities face protracted regulatory reviews, stringent labeling constraints, restrictive coverage determinations, and clinical burdens from diagnostic workups, potentially throttling volume ramp and compressing average realized selling prices.

  • Translational longevity biotechs and consumer metabolic wellness tools face clinical trial attrition and difficulty proving definitive morbidity reductions, risking consumer attrition, severe margin compression, and diminished pricing power across unproven health-optimization offerings.

  • Payer budgetary tightening, payer clawbacks or reimbursement denials, intensified pharmaceutical price competition, and macro pressures on discretionary consumer budgets threaten to curtail uptake of self-pay screenings, premium wellness products, and preventive health subscriptions.

Overview

Hiring Trend Watchpoints

High-performing operators in this theme show a decisive hiring shift away from generalist administrative overhead and toward specialized commercial payer access liaisons, clinical genomics sales reps, CLIA lab automation engineers, and regulatory specialists navigating direct-to-consumer diagnostics. In early detection and diagnostics (Guardant, Abbott/Exact, GRAIL), watch for headcount additions in billing operations and reimbursement recovery to counteract rising payer claim denials, alongside field specialists integrating blood tests into primary care and employer workflows. In digital health and consumer longevity platforms (Hims & Hers, Dexcom), watch for targeted engineering hires in AI-native clinical workflows, mobile UX for nutritional/metabolic coaching, and specialized compound pharmacy compliance personnel. Warning signs of theme deterioration include hiring freezes in molecular diagnostics commercial teams, R&D headcount reductions in aging biology pipelines (e.g., BioAge), or aggressive cuts in clinical utility trial management personnel.

Forum Watchlist

  • subreddit — r/longevityhigh

    Discussions on translational geroscience, clinical trial readouts for senolytics, NLRP3 inhibitors, APJ agonists, and regulatory pathways for aging interventions

  • subreddit — r/Biohackershigh

    Real-world consumer adoption of OTC continuous glucose monitors (Stelo, Lingo), biological age testing kits, longevity peptide protocols (sermorelin, NAD+), and preventive health tracking

  • subreddit — r/PeterAttiahigh

    Discussions on early cancer screening (Galleri, Shield), aggressive lipid management (ApoB, PCSK9 inhibitors), VO2 max optimization, and preventive clinical diagnostics

  • subreddit — r/cgmmedium

    User sentiment, adhesive/sensor durability, pricing friction, and software utility of OTC metabolic sensors for non-diabetic wellness and prediabetes tracking

  • subreddit — r/Semaglutidemedium

    Patient adherence, muscle preservation strategies, companion biomarker testing, and transitions from branded GLP-1s to telehealth platforms

Industry Publications

  • STAT News (statnews.com) — Premier biopharma, health tech, and longevity diagnostics reporting covering clinical trials, FDA review panels, and payer coverage decisions.
  • Fierce Biotech (fiercebiotech.com) — Deep analysis of early-to-mid stage pipelines targeting aging biology, cardiometabolic disease, and novel preventative therapeutic modalities.
  • GenomeWeb (genomeweb.com) — Authoritative industry coverage of liquid biopsy, molecular oncology, hereditary cancer screening, and clinical diagnostic reimbursement policies.
  • MedTech Dive (medtechdive.com) — Essential monitoring for FDA clearance milestones, wearable metabolic sensors, medical imaging advancements, and payer coding dynamics.
  • Endpoints News (endpts.com) — Breaking reporting on pharmaceutical pipeline milestones, GLP-1 and incretin clinical readouts, and executive talent moves across preventive medicine.

Second Order Trends

Several key second-order trends are emerging across the healthspan ecosystem: (1) The Convergence of Incretins and Biowearables: Continuous glucose monitors (Stelo, Lingo) are shifting from isolated biohacking gadgets into clinical companion tools for patients initiating GLP-1/GIP therapies, used to track dietary adherence and monitor glycemic volatility while safeguarding lean mass. (2) De-Medicalization into Employer-Paid Preventive Benefits: Multi-cancer early detection blood tests (Galleri) and advanced lipid/hereditary screening panels are bypassing traditional slow CMS paths by contracting directly with self-insured employers and Medicare Advantage plans as premium executive wellness and retention benefits. (3) D2C Telehealth Platform Verticalization: Direct-to-consumer health providers are expanding beyond acute lifestyle prescriptions into comprehensive longevity ecosystems, bundling regular at-home biomarker testing (e.g., Hims Labs) with preventive peptides, hormone therapy, and customized physician protocols. (4) AI-Augmented Routine Screening: Standard diagnostic imaging (GE HealthCare mammography and bone densitometry) and genomic profiling (Myriad Prolaris + AI) are integrating machine learning algorithms to generate multi-year predictive risk scores rather than single-point-in-time diagnostic assessments.

Search Keywords Brand Product

  • Galleri test
  • Shield blood test
  • Cologuard Plus
  • Lingo
  • Stelo
  • FreeStyle Libre
  • Zepbound
  • Mounjaro
  • Foundayo
  • Retatrutide
  • MariTide
  • Repatha
  • Gardasil 9
  • Shingrix
  • Arexvy
  • AirSense
  • myRisk
  • Precise MRD
  • OraQuick
  • Colli-Pee
  • healthspan extension
  • longevity medicine
  • preventive healthcare
  • multi-cancer early detection
  • liquid biopsy cancer screening
  • over-the-counter CGM
  • metabolic health monitoring
  • hereditary cancer risk testing
  • cardiometabolic risk reduction
  • adult immunization

Search Keywords Policy Regulatory

  • Medicare MCED coverage bill
  • MolDx local coverage determination
  • FDA over-the-counter clearance
  • USPSTF screening recommendations
  • American Cancer Society guidelines
  • PMA approval pathway
  • Medicare GLP-1 coverage

Search Keywords Event Phrases

  • FDA Advisory Committee Galleri
  • ASCO Annual Meeting
  • ADA Scientific Sessions
  • ESMO Congress
  • CMS National Coverage Analysis

Google Trend Product Category Intent

• buy over the counter CGM • early cancer blood test • multi cancer screening test cost • hereditary cancer gene test • at home hormone test • sleep apnea machine CPAP

Google Trend Consumer Intent

• how to improve healthspan • biological age test • metabolic health tracking • how to live longer • preventative health screening checklist • preventative heart disease test

Google Trend Macro Policy Terms

• Medicare coverage for cancer screening • insurance coverage continuous glucose monitor • GLP-1 Medicare coverage rules • FDA approved multi cancer test

Economic Data Watch

1. FRED — Retail and Food Services Sales

Matchedfred · access=api · map_only

Metric/field RSXFS

Cadence monthly

Why it matters Indicates consumer spending capacity, directly impacting self-pay segments for health monitoring, wellness products, health-focused retail, and fitness memberships.

Signal to watch Sustained increase in retail sales is bullish, suggesting healthy consumer demand.

Confidence: high

2. FRED — Personal Consumption Expenditures

Matchedfred · access=api · map_only

Metric/field PCEPI

Cadence monthly

Why it matters Reflects overall consumer and payer spending on healthcare services and products, influencing market size for diagnostics, devices, and pharmaceuticals.

Signal to watch Consistent growth in healthcare PCE indicates a favorable spending environment.

Confidence: high

3. FRED — Consumer Price Index

Matchedfred · access=api · map_only

Metric/field CPIMEDSL

Cadence monthly

Why it matters High medical inflation can pressure consumer discretionary spending on health and influence payer reimbursement decisions, affecting profitability for healthcare providers and product manufacturers.

Signal to watch Moderating medical care inflation could ease cost pressures and support broader access.

Confidence: high

4. FRED — All Employees, Health Care and Social Assistance

Matchedfred · access=api · map_only

Metric/field CES6562000001

Cadence monthly

Why it matters Indicates the overall health and growth of the healthcare sector, which drives demand for medical devices, diagnostics, and pharmaceutical products.

Signal to watch Consistent growth in healthcare employment suggests robust industry expansion and demand.

Confidence: high

5. Trading Economics — Japan Retail Sales Annual

Not in registryaccess=scrape

Metric/field Japan Retail Sales Annual

Cadence monthly

Why it matters Monitors consumer spending trends in key international markets like Japan, relevant for companies expanding globally (e.g., GRAIL, Abbott, Amgen, Lilly).

Signal to watch Sustained or increasing retail sales in international markets indicate expanding consumer demand.

Confidence: medium

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Not in registry

Metric/field Study Status, Last Update Posted for 'obesity' OR 'cancer screening' OR 'aging biology' OR 'metabolic health'

Cadence event_driven

Why it matters Monitors progress and outcomes of clinical trials for new drugs and diagnostics in obesity, cancer detection, and longevity, impacting companies like LLY, AMGN, BIOA, GH, GRAL.

Signal to watch Positive trial outcomes and advancement to later phases are bullish for future product launches.

Confidence: high

2. FDA — Medical Device 510(k) Clearances and PMA Approvals

Not in registry

Metric/field device_name, decision_date for 'continuous glucose monitor' OR 'multi-cancer early detection' OR 'biowearable'

Cadence daily

Why it matters FDA approvals and clearances are critical for launching new medical devices and diagnostics, directly impacting revenue growth and market penetration for companies like DXCM, ABT, GRAL.

Signal to watch Timely approvals and broad labels are bullish for market access and adoption.

Confidence: high

3. Google Trends — Search Interest

Not in registry

Metric/field search volume for 'how to improve healthspan' OR 'early cancer blood test' OR 'buy over the counter CGM'

Cadence weekly

Why it matters Proxies general consumer interest and intent for proactive health, early detection, and metabolic monitoring, indicating potential demand for theme products and services.

Signal to watch Sustained or increasing search interest over time is bullish for market adoption.

Confidence: medium

4. Regulations.gov — Federal Register / Regulations.gov Dockets

Not in registry

Metric/field docket status for 'Medicare GLP-1 coverage' OR 'MCED coverage' OR 'FDA OTC biosensor'

Cadence event_driven

Why it matters Monitors policy and regulatory developments that can significantly impact market access and reimbursement for key products in the theme (e.g., GLP-1s, MCED tests, OTC biosensors).

Signal to watch Favorable policy changes and expanded coverage are bullish for companies in the theme.

Confidence: high

5. Reddit — Subreddit Activity

Not in registry

Metric/field post volume, subscriber count for r/longevity OR r/Biohackers

Cadence daily

Why it matters Provides insights into consumer and enthusiast discussions, sentiment, and emerging trends related to healthspan extension, aging biology, and wearable tech.

Signal to watch Increasing activity and positive sentiment indicate growing interest and potential market adoption.

Confidence: medium

Paid Alt Data Watch

1. IQVIA — Healthcare Claims / Rx

Matchediqvia_medical_claims · access=file · map_only

Metric/field Total Prescriptions (TRx) and New-to-Brand Prescriptions (NBRx) for GLP-1s (e.g., Zepbound, Mounjaro), CGM (e.g., Dexcom G7, Abbott Libre), and cancer diagnostics (e.g., Galleri, Shield)

Cadence weekly

Why it matters Provides real-time insights into prescription volumes, new patient uptake, and market share for key drugs and devices, directly reflecting commercial success and adoption.

Signal to watch Consistent week-over-week or month-over-month growth in TRx and NBRx is bullish.

Confidence: high

2. Similarweb — Web / App / Clickstream Data

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic, app downloads, and engagement metrics for Hims & Hers, Dexcom, Basic-Fit, Sprouts Farmers Market, OraSure (OraQuick)

Cadence weekly

Why it matters Tracks digital engagement and customer acquisition trends for consumer-facing health and wellness platforms, indicating user adoption and brand strength.

Signal to watch Increasing website traffic, app downloads, and user engagement are bullish indicators.

Confidence: high

3. Definitive Healthcare — Healthcare Claims / Rx

Not in registry

Metric/field Physician prescribing patterns and referral volumes for multi-cancer early detection tests (e.g., Galleri, Shield) and hereditary cancer testing (e.g., MyRisk)

Cadence monthly

Why it matters Provides granular data on clinician adoption and utilization of advanced diagnostic tests, crucial for understanding market penetration beyond self-pay.

Signal to watch Increasing prescribing and referral volumes from a growing base of clinicians are bullish.

Confidence: high

4. Hatched Analytics — Card / Transaction Data

Matched (medium)hatched_analytics_ticker_level_transaction_digital_kpi_feeds · access=file · map_only

Metric/field Consumer spending and transaction volume at health & wellness retailers (e.g., Sprouts Farmers Market) and fitness chains (e.g., Basic-Fit)

Cadence weekly

Why it matters Offers direct insight into consumer spending habits on healthy food and fitness memberships, reflecting demand for proactive health choices.

Signal to watch Sustained growth in transaction volume and average spend is bullish.

Confidence: high

5. HealthVerity — Multi-source / Aggregated Patient Data

Matchedhealthverity_lab_data · access=file · map_only

Metric/field Patient journey data, diagnosis rates, and treatment adherence for cardiometabolic diseases, sleep apnea, and early-stage cancers

Cadence monthly

Why it matters Provides a comprehensive view of disease progression, diagnostic rates, and treatment effectiveness, informing market potential and product impact for companies like LLY, AMGN, RMD, GH, GRAL.

Signal to watch Increasing early diagnosis rates and improved treatment adherence are bullish for theme companies.

Confidence: high

Prediction Market Watch

1. Hims subscribers in 2026

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxhimsa

Why it matters Hims & Hers (HIMS) is a key constituent in this theme, focusing on proactive health monitoring and weight loss. Subscriber growth directly reflects consumer adoption of its services, impacting revenue and stock performance.

Series key pm_hims_subscribers_2026

2. When will CMS announce the addition of GLP-1 drugs for obesity to Part D? (Before Jan 20, 2029)

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxpartdglp1

Why it matters Medicare (CMS Part D) coverage for GLP-1 drugs for obesity is a critical regulatory and funding driver for theme constituents like Eli Lilly (LLY) and Hims & Hers (HIMS). Expanded coverage would significantly broaden market access and reimbursement, directly impacting revenue and the theme's thesis of proactive health and disease-risk reduction.

Series key pm_cms_glp1_partd_coverage

Theme Plain English
This theme captures companies capitalizing on the structural shift from reactive sick care toward proactive healthspan extension and disease prevention. It encompasses over-the-counter metabolic biowearables, multi-cancer early detection blood tests, hereditary genomic screening, next-generation obesity and cardiometabolic therapeutics, adult preventive vaccines, and accessible physical wellness and nutrition. Together, these businesses monetize early diagnostic intervention, metabolic risk reduction, and everyday behavioral lifestyle choices that preserve functional longevity before chronic disease manifests.
Key Metrics3 rows
MetricCadenceWhat It SignalsUpdate Source
Preventive Diagnostics & Monitoring Adoption RateQuarterlyBullish: Sustained double-digit growth in test/monitoring volumes indicates increasing adoption of early detection and proactive health management. Bearish: Slowing growth or declining volumes suggest market saturation, reimbursement hurdles, or lack of perceived utility.LLM_Approved
Adoption of Next-Gen Preventive & Healthspan TherapiesWeekly/Monthly (IQVIA), Quarterly (aggregated from earnings)Bullish: Accelerating Total Prescriptions (TRx) and New-to-Brand Prescriptions (NBRx) growth indicates strong market penetration and acceptance of advanced therapies. Bearish: Deceleration or plateauing suggests competitive pressures, access issues, or efficacy concerns.LLM_Approved
Insurance Coverage Expansion for Healthspan TechnologiesEvent-driven (as policies change), Quarterly (summarized in earnings/investor calls)Bullish: Broadening coverage by major commercial payers and government programs (Medicare/Medicaid) unlocks significant market access and reduces out-of-pocket costs, driving adoption. Bearish: Delays, restrictive policies, or lack of new coverage agreements limit market penetration and revenue growth.LLM_Approved
Upcoming Catalysts45 rows
CatalystEstimated TimingEstimated Date StartEstimated Date EndWhy It MattersTicker Or Theme SpecificSource TypesContributing TickersMention CountBase ScoreSource WeightSpecificity WeightMacro BridgeMacro Bridge MultiplierTheme ScoreDate AggregatedManual OverrideBridge Mention CountTheme Base ScoreTheme Importance ScoreSource TypeCatalyst SourceCatalyst IDTranscript Date
Dexcom is on track to achieve nearly 50% U.S. customer conversion to its G7 15-day continuous glucose monitoring (CGM) system. This rollout is also expanding internationally.By Year-End 20262026-11-132026-12-31The widespread adoption of advanced CGM systems like Dexcom G7 is fundamental to the theme's focus on proactive health monitoring and continuous metabolic feedback. Increased conversion and international rollout signify broader consumer engagement with tools for managing metabolic health, supporting behavioral changes and disease-risk reduction.Tickertheme_composerDXCM10.00051.181.01.00.05812026-11-13False10.00560.6576theme_composerTheme composer
Hims & Hers is awaiting the FDA's 'full and final rule-making' regarding certain peptide therapies, specifically BPC-157 and TB-500. This regulatory clarity will impact the commercialization of its Peptides+ offering.Ongoing, timing uncertain2026-11-132027-12-31Regulatory clarity on peptides is crucial for the theme's emerging aging-biology interventions. It will define the market for new longevity-science exposures and directly impact HIMS's ability to expand its proactive health monitoring and treatment platform into this high-growth area.Themetheme_composerHIMS13.61.180.85Regulatory/Policy1.35487.4582026-11-13False10.0010.141theme_composerTheme composer
European regulatory approval for Foundayo (chronic weight management and type 2 diabetes) following a positive CHMP opinion.by year end2026-10-012026-12-31This approval is crucial for the anticipated global rollout of Foundayo in major markets in 2027, significantly expanding its international revenue potential.Tickerearnings_transcriptLLY (ticker)LLY_10dadbeb2026-10-29
Readout of Foundayo Phase 3 trial in obstructive sleep apnea.later this year2026-10-012026-12-31Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications.Tickerearnings_transcriptLLY (ticker)LLY_48d9403d2026-08-05
U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes.later this year2026-10-012026-12-31This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth.Tickerearnings_transcriptLLY (ticker)LLY_696cb5692026-08-05
Launch of Orforglipron in a few international markets (e.g., UAE).a few markets late in 20262026-10-012026-12-31This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration.Tickerearnings_transcriptLLY (ticker)LLY_cf82d1b52026-02-04
FDA provides perspective on explicit rule-making for peptides, specifically TB-500 and BPC-157, following the comment period.in the next couple of weeks2026-11-102026-11-24Regulatory clarity is essential for Hims & Hers to launch these specific peptides, which could significantly expand their peptide offering and market opportunity, aligning with the broader GLP-1 theme.Themeearnings_transcriptHIMS (ticker)HIMS_18421c702026-11-09
Hims & Hers launches its Peptides+ offering, including sermorelin, glutathione, and NAD+, with clinician-led treatment plans and access to regular blood testing.later this month2026-11-012026-11-30This expands the platform into a new, complex care category, leveraging their infrastructure and potentially driving new revenue streams and customer engagement in the longevity and wellness space.Tickerearnings_transcriptHIMS (ticker)HIMS_7869cc522026-11-09
Hims & Hers will launch flexible multi-month subscriptions across its weight loss assortment and expand access to Lilly's GLP-1 medications, Zepbound and Foundayo.ahead of the new year2026-10-012026-12-31This broadens treatment options and improves pricing flexibility, potentially increasing customer acquisition, retention, and market share in the high-growth metabolic health category.Tickerearnings_transcriptHIMS (ticker)HIMS_d8f2182b2026-11-09
Hims & Hers anticipates its AI-native experience will reach nearly 100% of weight loss subscribers.before the end of the year2026-10-012026-12-31This is expected to drive higher engagement, better adherence, and improved customer satisfaction, leading to stronger retention and potentially lower churn.Tickerearnings_transcriptHIMS (ticker)HIMS_aa0601242026-11-09
Potential Medicare coverage expansion for Libre Continuous Glucose Monitoring (CGM) for Type 2 non-insulin users in the US.in the fall2026-09-012026-11-30This could unlock a multibillion-dollar opportunity by accelerating commercial insurance coverage and reaching approximately 10 million Medicare beneficiaries, significantly boosting CGM sales.Tickerearnings_transcriptABT (ticker)ABT_79370e412026-07-16
FDA approval and US launch of Amulet 360 Left Atrial Appendage (LAA) device.by year-end 20262026-10-012026-12-31This device is designed to help reduce the risk of stroke in patients with AFib and is expected to reignite growth and capture market share in the LAA closure market.Tickerearnings_transcriptABT (ticker)ABT_30e24e432026-10-21
Broad U.S. launch of TactiFlex Duo catheter.starting in the fourth quarter2026-10-012026-12-31This catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure, which is expected to drive adoption and market share in electrophysiology.Tickerearnings_transcriptABT (ticker)ABT_7cc559f22026-10-21
Launch of Volt PFA catheter in Japan.sometime in Q42026-10-012026-12-31This launch is expected to turn Japan from a headwind to a tailwind for the electrophysiology business, contributing to international growth acceleration.Tickerearnings_transcriptABT (ticker)ABT_8bb43b0e2026-10-21
Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication.We will update you on those discussions as necessary.2026-04-242026-12-31The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory.Tickerearnings_transcriptAMGN (ticker)AMGN_fe4d51bf2026-02-03
CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies.Final rule publication in November 2026; effective January 1, 2027.2026-11-012027-01-01This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings.Themeearnings_transcriptDXCM (ticker)DXCM_805547792026-07-30
CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data.before the end of this year2026-08-072026-12-31This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers.Tickerearnings_transcriptDXCM (ticker)DXCM_e0606eaf2026-07-30
Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system.by year end2026-10-012026-12-31This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins.Tickerearnings_transcriptDXCM (ticker)DXCM_b887655c2026-07-30
Clinical launch of Reveal Ultra, the newest addition to Guardant Health's oncology portfolio.before year-end2026-11-052026-12-31Reveal Ultra is expected to demonstrate market-leading sensitivity in minimal residual disease (MRD) detection, potentially setting a new performance bar and unlocking a significant new growth opportunity for the oncology business.Tickerearnings_transcriptGH (ticker)GH_4a8220c92026-11-05
Guardant Health plans to launch Reveal Ultra, which is anticipated to be the most sensitive tumor-informed MRD test.later this year2026-10-012026-12-31This new product launch is expected to redefine sensitivity in the tumor-informed MRD space, enhancing Guardant Health's competitive position and driving further volume growth in the MRD market.Tickerearnings_transcriptGH (ticker)GH_707b8be02026-07-30
Second readout from the ATLAS-UC trial for tulisokibart in moderately to severely active ulcerative colitis.second half of 20262026-09-012026-12-31This readout, combined with the earlier induction study, will form the basis of a regulatory filing, reinforcing confidence in the program's potential and expanding Merck's immunology portfolio.Tickerearnings_transcriptMRK (ticker)MRK_bcd577c22026-08-04
Sprouts Farmers Market expects a one-time year-over-year gross margin benefit in the fourth quarter of 2026.fourth quarter2026-10-012026-12-31This benefit is due to cycling an easier shrink comparison and the full-year impact of loyalty program changes (from $2 to $1), which is expected to slightly increase gross margins.Tickerearnings_transcriptSFM (ticker)SFM_c0b54a882026-07-29
Sequential comparable store sales improvement and return to long-term financial algorithmlate in the year2026-10-012026-12-31Management expects comps to rebound in the second half of 2026 as they lap easier comparisons and benefit from loyalty initiatives. Failure to show this improvement would suggest structural issues with traffic or a more severe consumer downturn.TickerSFM (ticker)SFM_c3aa9cfe2026-02-19
Execution of at least $300 million in share repurchasesin 20262026-02-192026-12-31This capital allocation plan is baked into the EPS guidance; a failure to execute the full amount due to cash flow constraints or alternative capital needs would negatively impact EPS growth and signal a shift in management's outlook.TickerSFM (ticker)SFM_510092a22026-02-19
U.S. launch of Libre Duo, the world's first dual glucose ketone biowearable sensor.in December2026-12-012026-12-31This product allows people with diabetes to monitor ketones without traditional blood or urine tests, offering a new growth driver for the diabetes care business.Tickerearnings_transcriptABT (ticker)ABT_6009f9062026-10-21
Resumption of the legacy Illumina royalty payments.late December 20262026-12-012026-12-31This will negatively impact gross margins, with the full effect observed in Q1 2027, affecting the company's profitability.Tickerearnings_transcriptGRAL (ticker)GRAL_4b5b6dac2026-11-04
Eli Lilly's Innovation Day will provide updates on its pipeline, including next-generation incretins like retatrutide and Olora-TZP, and other therapeutic areas.December 7, 20262026-12-072026-12-07Lilly's pipeline updates are highly relevant to the theme's focus on advances in obesity medicine and aging-biology research. Positive data or new development plans for next-generation cardiometabolic therapies could significantly expand clinically supported interventions aimed at delaying chronic disease and preserving physical function.Tickertheme_composerLLY15.881.181.051.0728.5322026-11-13False10.248530.7951theme_composerTheme composer
Lilly Innovation Day.December 7th2026-12-072026-12-07This event is expected to provide more detailed insights into Lilly's pipeline, potentially revealing new material information about future growth drivers and strategic priorities.Tickerearnings_transcriptLLY (ticker)LLY_a24ab55b2026-10-29
Impact of the 53rd week in the fiscal 2026 calendarend of the fourth quarter2026-12-282027-01-03The extra week is expected to contribute approximately $200 million in sales and $0.21 in diluted EPS. This creates a non-comparable financial year that could skew year-over-year growth metrics and investor sentiment if not properly adjusted.TickerSFM (ticker)SFM_44566cb62026-02-19
GRAIL's Galleri multi-cancer early detection test is anticipated to receive FDA Premarket Approval (PMA). This approval is crucial for establishing Galleri as the 'gold standard' MCED and unlocking broader payer and employer adoption.Early Q1 20272027-01-012027-03-31FDA approval for Galleri is a pivotal moment for the theme, as it validates population-level cancer screening and shifts healthcare towards earlier diagnosis and disease-risk reduction. It will likely create a bifurcated market, significantly impacting GRAL's market access and potentially influencing the competitive landscape for other early detection players.Themetheme_composerGRAL, GH, ABT30.00631.181.0Regulatory/Policy1.350.99642026-11-13False20.44871.3588theme_composerTheme composer
Myriad Genetics anticipates securing reimbursement for its Precise MRD (Minimal Residual Disease) test in breast cancer. This will expand the test's commercial availability and adoption in recurrence monitoring.First Half 20272027-01-012027-06-30This catalyst is important for the theme's focus on earlier diagnosis and disease-risk reduction by enabling more precise monitoring of cancer recurrence. Successful reimbursement for Precise MRD will drive revenue growth for MYGN and demonstrate progress in integrating advanced diagnostics into standard care pathways.Themetheme_composerMYGN20.01.180.92Regulatory/Policy1.350.00192026-11-13False20.200129.329theme_composerTheme composer
U.S. regulatory submission (BLA pathway) for retatrutide.Q1 20272027-01-012027-03-31This submission is a critical step towards bringing the highly efficacious triple agonist, retatrutide, to market, potentially solidifying Lilly's leadership in cardiometabolic health with a drug demonstrating unprecedented weight loss.Tickerearnings_transcriptLLY (ticker)LLY_a075099b2026-10-29
Significant U.S. payer formulary coverage for Libre goes into effect.January 12027-01-012027-01-01This expanded coverage is expected to be a nice growth driver for the diabetes business in the coming year.Tickerearnings_transcriptABT (ticker)ABT_c375ff522026-10-21
CMS system update to process claims for the new Guardant360 Liquid CDx billing code.January 20272027-01-012027-01-31This update will enable CMS to process claims for Guardant360 Liquid CDx, resolving a temporary delay and allowing Guardant Health to receive an estimated $10 million to $15 million in payments deferred from the second half of 2026, improving cash flow.Tickerearnings_transcriptGH (ticker)GH_f1eab5ab2026-11-05
Receipt of ADLT (Advanced Diagnostic Laboratory Test) designation for Guardant360 Liquid CDx.in the first half of 20272027-01-012027-06-30ADLT designation is expected to lead to an uplift in the average selling price (ASP) for Guardant360 Liquid CDx towards the Medicare price of $8,455, significantly improving reimbursement and gross margins.Tickerearnings_transcriptGH (ticker)GH_5318cd0f2026-11-05
Guardant Health plans to offer widespread availability of Guardant360 Liquid CDx to U.S. customers.following ADLT designation2027-01-012027-06-30This commercial rollout, following ADLT designation, will drive greater adoption of the test, simplify the therapy selection portfolio, and contribute to oncology volume growth.Tickerearnings_transcriptGH (ticker)GH_8850e4c82026-07-30
Guardant Health remains on track to obtain ADLT designation for Guardant360 Liquid CDx.first half of 20272027-01-012027-06-30This designation is expected to lead to an immediate increase in the average selling price (ASP) for Guardant360, improving gross margins and potentially accelerating the company's timeline to cash flow breakeven.Tickerearnings_transcriptGH (ticker)GH_4fe268e12026-07-30
FDA final decision on the premarket approval (PMA) application for Galleri.by early Q1 of 20272027-01-012027-03-31This is a pivotal catalyst expected to create a market bifurcation, establish Galleri as the gold standard MCED, and unlock broader payer and employer adoption, serving as the gateway for Medicare coverage.Tickerearnings_transcriptGRAL (ticker)GRAL_ea568ad22026-11-04
FDA approval of the Galleri multi-cancer early detection test following its Premarket Approval (PMA) application.in the first part of 20272027-01-012027-06-30FDA approval would provide critical regulatory validation, de-risk the technology, and pave the way for broader commercialization, payer coverage, and physician adoption.Tickerearnings_transcriptGRAL (ticker)GRAL_1d85fec42026-08-05
Closing of the definitive agreement to sell Myriad's Prenatal Health business to Labcorp.by early 2027, with an outside date of Feb 19, 20272027-01-012027-02-19This transformational transaction is expected to significantly improve Myriad's financial profile, including revenue growth, profitability, and liquidity, by allowing the company to focus on the Cancer Care Continuum.Tickerearnings_transcriptMYGN (ticker)MYGN_455de9982026-11-04
Full commercial launch of Precise MRD.Q1 of 20272027-01-012027-03-31This represents the broader commercialization of the Precise MRD platform, significantly expanding its market reach and revenue potential across multiple cancer types.Tickerearnings_transcriptMYGN (ticker)MYGN_3a65a0782026-05-05
Site approvals and expansion into the Midwest and Northeast regions2027 and beyond2027-01-012027-12-31Laying the foundation for growth in these new territories is vital for the company's long-term expansion strategy. Successful site approvals and subsequent performance in these regions will determine if the Sprouts format is truly national in scale.TickerSFM (ticker)SFM_5d6093a92026-02-19
Transition to a more balanced quarterly store opening cadence20272027-01-012027-12-31A more balanced opening schedule in 2027 would reduce the heavy back-half pressure on the P&L seen in 2025 and 2026, potentially leading to more consistent quarterly earnings performance.TickerSFM (ticker)SFM_7001504d2026-02-19
Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months.within 12 to 18 months2027-02-232027-08-23Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion.Tickerearnings_transcriptHIMS (ticker)HIMS_8ce0db052026-02-23
FDA approval of the PMA (Premarket Approval) application for Guardant360 Tissue.sometime next year in terms of approval2027-11-052027-12-31A successful FDA approval would provide the highest level of regulatory clearance for Guardant360 Tissue, further supporting its rapid growth and potentially opening an ADLT pathway for the test, which could provide upside opportunity for reimbursement.Tickerearnings_transcriptGH (ticker)GH_0d77252a2026-11-05
NotesTable

Earnings Summary

DateTypeCommentDetailSentimentTickers
2026-11-13Theme Refresh SynthesisThe theme sees strong tailwinds from expanding access to early detection and metabolic health solutions. Anticipated FDA approval for GRAIL's Galleri and broader CGM reimbursement for Dexcom signify growing adoption of proactive diagnostics. Lilly and Amgen advance next-gen obesity/cardiovascular therapies, while Hims & Hers expands into peptides and biomarker testing, despite subscriber volatility. Myriad focuses on cancer care, facing reimbursement hurdles.

Earnings Summary

BullishGRAL, DXCM, LLY, AMGN, HIMS, MYGN, ABT, MRK, SFM, BFIT.AS, GH, GSK, BIOA, GEHC, OSUR, RMD

News

4 stories tagged to this theme — Narrative Radar and editorial picks.

Loading correlation…

Constituents

  • LLYT13.5%
    — Eli Lilly and Company
  • HIMST11.5%
    — Hims & Hers Health, Inc.
  • ABTT3
    — Abbott Laboratories
  • — Amgen Inc.
  • — DexCom, Inc.
  • GHT3
    — Guardant Health, Inc.
  • — GRAIL Inc.
  • MRKT3
    — Merck & Co., Inc.
  • — Myriad Genetics, Inc.
  • SFMT3
    — Sprouts Farmers Market, Inc.
  • BFIT.AST3
    · no notes yet
  • BIOAT3
    · no notes yet
  • GEHCT3
    · no notes yet
  • GSKT3
    · no notes yet
  • OSURT3
    · no notes yet
  • RMDT3
    · no notes yet